How much does stem cell therapy for Primary Immunodeficiency cost? (2026)
The comparison dataset stores a Bulgaria planning observation of €3,000–€8,000 for treatment, compiled from cited public commercial sources. It is not a quotation from Stem Plus, and different products, doses, visits and inclusions must not be treated as equivalent. The stored registry query contains 92 Primary Immunodeficiency records. Registration does not mean that a study is recruiting, that a person is eligible, or that treatment and travel are free; verify the current record and sponsor-cost terms directly.
Primary immunodeficiencies, also called inborn errors of immunity, comprise many genetic disorders with different infection, inflammatory, autoimmune and malignancy risks. Haematopoietic stem-cell transplantation (HSCT) can be established or potentially curative for selected severe diagnoses because it replaces the blood-forming immune system. This is not equivalent to an MSC infusion marketed for general immune support.
What drives the cost for Primary Immunodeficiency
Separate diagnostic genetics, donor search, product procurement, conditioning, admission, infection prophylaxis, long-term follow-up and complication care. Obtain a transplant centre and insurer decision for the exact diagnosis or a sponsor statement for a trial. Do not compare this pathway with a same-day commercial infusion by price alone.
Evidence and eligibility are diagnosis-, genotype-, donor- and centre-specific. HSCT may require conditioning and carries infection, graft failure, graft-versus-host disease and organ-toxicity risks; some disorders instead use immunoglobulin, antimicrobial, targeted immune or gene-based treatment. The NIAID GATA2-deficiency factsheet illustrates diagnosis-specific use of HSCT. It cannot validate a generic placental, stromal or exosome product.
Primary Immunodeficiency cost by country — comparison (2026)
| Location | Indicative treatment cost | Regulation |
|---|---|---|
| Bulgaria (EU) · e.g. Stem Plus | €3,000–€8,000 | Verify provider and laboratory certificates |
| USA | €4,600–€46,000 | Non-EU; verify provider and product status |
| UK | €4,880–€49,000 | Non-EU; verify provider and product status |
| Germany | €11,000–€36,700 | EU member state; verify provider and product status |
| Switzerland | €20,000–€40,000 | Non-EU; verify provider and product status |
| Mexico | €3,000–€12,000 | Non-EU; verify provider and product status |
| India | €3,000–€8,000 | Non-EU; verify provider and product status |
| Serbia | €7,000–€31,000 | Non-EU; verify provider and product status |
| Turkey | €6,000–€18,000 | Non-EU; verify provider and product status |
| Thailand | €8,000–€20,000 | Non-EU; verify provider and product status |
| Panama | €15,000–€27,000 | Non-EU; verify provider and product status |
Price varies with cell type, dose, number of sessions, diagnostics, supportive care and follow-up. A lower range does not establish equivalent quality or outcome. Request a fixed written quote and verify the therapy and provider with the relevant authorities. Check registered trials before paying privately.
Primary Immunodeficiency cost — common questions
Why is Primary Immunodeficiency stem-cell treatment so much cheaper in Bulgaria?
The collected commercial ranges differ, but they may describe different products, doses, visits and inclusions. A lower quote does not establish equivalent quality, evidence or regulatory status.
Is a cheaper programme riskier?
Price alone cannot establish risk. Verify the exact treatment status, provider and manufacturing authorisations, product identity, release testing, adverse-event plan and primary evidence.
Does the price include travel and hotel?
The €3,000–€8,000 range covers the medical programme. Add flights, hotel and recovery with our calculator for your true all-in cost from your city.
Will I get a fixed quote, or an open-ended bill?
Ask for a written quotation after clinical review, with the exact product, inclusions, exclusions, cancellation terms and circumstances in which charges may change. A website estimate is not a binding quote.
Sources & further reading
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
- Open clinical trials for Primary Immunodeficiency (ClinicalTrials.gov) ↗
- Peer-reviewed research on PubMed ↗
- ISSCR patient guide — what to ask ↗
- FDA consumer warning on stem-cell therapies ↗
- EMA — advanced-therapy (ATMP) framework ↗
- Clinic perspective — Stem Plus on Primary Immunodeficiency ↗
Indicative ranges for planning, compiled from public market data; confirmed pricing follows a medical review. Not medical advice.